Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
8 hedge funds and large institutions have $14.3M invested in Better Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$3.22M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$2.96M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$1.97M |
| 4 |
MSU
Mizuho Securities USA
New York
|
+$1.87M |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$1.45M |
Top Sellers
BTTX Hedge Fund Activity: Q1 2021 in Review
8 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q1 2021, worth a combined $14.3M.
Buyers outnumbered sellers: 8 funds opened new BTTX positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $3.22M.
- 8 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $14.3M of Better Therapeutics, Inc. Common Stock stock for Q1 2021.
- 8 funds opened new Better Therapeutics, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +8 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q1 2021 was Glazer Capital LLC, an estimated $3.22M added.
Based on aggregated 13F filings for Q1 2021.